A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

To join this study, adults must have been diagnosed with follicular lymphoma (grades 1-3a) or marginal zone lymphoma (nodal, splenic, or outside of organs). Your lymphoma needs to have either come back after at least one previous treatment, or it didn't respond to previous treatments. These treatments must have included a specific type of drug called an anti-CD20 therapy.

Doctors will need to be able to measure your lymphoma using scans like CT or MRI. You should be generally well enough to take part in a study, meaning you can mostly go about your daily activities. You'll also need to have healthy blood counts and organ function. Importantly, if you can become pregnant or get someone pregnant, you must understand the risks of lenalidomide to unborn babies and agree to use effective contraception.

If you decide to take part, the first part of the study will involve finding the right dose of the new drug, odronextamab, when combined with lenalidomide. In the second part, you would be randomly assigned to receive either the new combination (odronextamab plus lenalidomide) or the standard treatment (rituximab plus lenalidomide). This is like tossing a coin, so neither you nor your doctor can choose which treatment you get.

Throughout the study, you'll have regular hospital visits for check-ups, blood tests, and scans to monitor your lymphoma and side effects. You'll also be asked questions about how you feel and how the treatment affects your daily life. You'll need to take the study medication as instructed and follow specific precautions, especially regarding pregnancy risks if you are taking lenalidomide. The total duration of your participation will depend on how you respond to the treatment and the study plan, but it generally involves ongoing monitoring and follow-up.